News
CRBU
2.152
+10.36%
0.202
Three Best Genomics Stocks for Your Portfolio in 2026
NASDAQ · 1d ago
Weekly Report: what happened at CRBU last week (0406-0410)?
Weekly Report · 1d ago
Caribou Biosciences announces annual shareholder meeting notice
Reuters · 4d ago
Caribou Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 04/07 11:17
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Benzinga · 04/07 11:06
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG), Caribou Biosciences (CRBU) and Praxis Precision Medicines (PRAX)
TipRanks · 04/07 10:10
Weekly Report: what happened at CRBU last week (0330-0403)?
Weekly Report · 04/06 10:03
Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
NASDAQ · 04/02 13:03
Caribou says FDA grants RMAT designation for CB-011 multiple myeloma CAR-T therapy
Reuters · 03/31 21:43
Caribou says FDA grants RMAT designation to CB-011 allogeneic BCMA CAR-T therapy
Reuters · 03/31 21:21
BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences
Reuters · 03/31 16:19
Caribou Biosciences Gains RMAT Status for CB-011 Therapy
TipRanks · 03/31 15:10
BUZZ-U.S. STOCKS ON THE MOVE-Stryker, TD Synnex, Factset
Reuters · 03/31 13:08
Caribou rises on FDA RMAT designation for CAR-T therapy
Seeking Alpha · 03/31 12:43
BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy
Reuters · 03/31 12:22
Caribou CB-011 granted Regenerative Medicine Advanced Therapy designation
TipRanks · 03/31 12:21
Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma
Benzinga · 03/31 12:02
CARIBOU BIOSCIENCES ANNOUNCES THE FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO CB-011, AN ALLOGENEIC ANTI-BCMA CAR-T CELL THERAPY
Reuters · 03/31 12:01
Weekly Report: what happened at CRBU last week (0323-0327)?
Weekly Report · 03/30 10:04
Weekly Report: what happened at CRBU last week (0316-0320)?
Weekly Report · 03/23 10:00
More
Webull provides a variety of real-time CRBU stock news. You can receive the latest news about Caribou Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.